Henry Schein, Inc.

HSIC Healthcare · Medical Distribution
Delayed 15 min
Last close
$84.29
Jun 29, 2026
52-week range
$61.95 — $89.29
-6% from high
Market cap
9.6B
Diluted basis
Dividend yield
No dividend declared
P/E
25.5
Trailing
Filing.fyi verdict · Jun 29, 2026

Fairly valued.

Fairly Valued (Neutral) — Filing.fyi's reading derived from the latest 10-K and forensic scores.

Neutral
RED DEEP / 100
Composite Health
AI synthesis · grounded in this ticker's SEC filings · drag to highlight, releases the composer

What the filing actually says.

AI · wry-editorial preset

Henry Schein’s 2026 Q1 10-Q presents a concise snapshot of operations for the three months ended March 28, 2026. The filing notes a net sales increase to $3,368 million, up from $3,168 million in the prior year period, representing a 6.3% rise. Despite this top-line growth, net income — the company’s profit after all expenses and taxes — saw a marginal decrease from $113 million to $112 million. This indicates a compression of profitability, even as gross profit, the revenue remaining after deducting cost of sales, rose from $1,000 million to $1,070 million. The filing also highlights a reduction in restructuring and related costs, decreasing from $25 million to $12 million, which partially offset other expense increases. Other expense, net, also increased slightly from $30 million to $32 million.

A quantitative forensic assessment of this filing is constrained by the absence of standard metrics. Beneish’s 1999 eight-ratio earnings-manipulation detector, Altman’s Z″ — a 1968 bankruptcy-distress index, and Piotroski’s F-Score, a 9-point fundamental strength scan, are all unavailable. Similarly, the Fog Index — a readability score where 12 equals newspaper and 18+ is obfuscatory — cannot be calculated from the provided excerpts. Without these established benchmarks, a comprehensive, ratio-driven analysis of potential accounting anomalies or financial health trends remains limited to the raw figures presented in the filing.

Delving into the operating results, the MD&A reveals that while net sales and gross profit increased, selling, general and administrative expenses rose from $738 million to $809 million year-over-year. This significant increase in operational overhead, a 9.6% rise, outpaced the growth in gross profit, directly contributing to the marginal decline in net income. Depreciation and amortization expenses also saw a modest increase from $62 million to $67 million. Furthermore, the balance sheet indicates an increase in accounts receivable, net of allowance for credit losses, from $1,651 million to $1,719 million. Inventories, net, also saw a slight rise from $2,002 million to $2,014 million. These shifts in working capital components, particularly the growth in receivables, warrant attention as they can sometimes signal changes in collection efficiency or revenue recognition practices.

This 10-Q provides a quarterly update on Henry Schein’s financial performance, detailing specific revenue, expense, and balance sheet figures for the period. It offers a factual basis for understanding recent operational trends, such as the interplay between sales growth and expense management. However, the filing, as excerpted, does not offer the qualitative context or forward-looking statements necessary to assess the security’s intrinsic value or future trajectory. It cannot, for instance, illuminate the competitive landscape, regulatory changes, or broader economic factors that might influence long-term prospects. A complete investment decision requires integrating this data with a wider array of information, including market conditions and industry-specific insights not present here.

SEC filings · last 12 months

Filing timeline

View all on EDGAR →
  • May 5, 2026
    10-Q
    Quarterly report (2026-03-28)Period: 2026-03-280
    Read →
  • May 5, 2026
    8-K
    Material event (2026-05-05)### Item 2.02 and the press release attached as Exhibit 99 .1 are considered furnished to the Securities and Exchange Commission and are not deemed filed for pu0
    Read →
  • Apr 8, 2026
    DEF 14A
    Proxy statement (2026-05-21)0
    Read →
  • Feb 24, 2026
    8-K
    Material event (2026-02-24)### Item 2.02 and the press release attached as Exhibit 99 .1 are considered furnished to the Securities and Exchange Commission and are not deemed filed for pu0
    Read →
  • Feb 24, 2026
    10-K
    Annual report (2025-12-27)Period: 2025-12-270
    Read →
  • Jan 12, 2026
    8-K
    Material event (2026-01-09)No specific items found in 8-K.0
    Read →
Member feature · Custom Q&A
Ask anything about HSIC's filings.
Plain-English answer, cited from the company's own 10-K and recent 10-Qs. No buy/sell advice.
Ask a question →
Further reading · curated for this filing

If this case caught your eye

Affiliate links — Filing.fyi earns a commission on Amazon purchases. We pick the books first, attach the link second.

Financial Shenanigans

Howard M. Schilit

Schilit's framework for the seven shenanigan types is the standard reference for the kind of MD&A pattern-matching this site does.

View on Amazon →

The Interpretation of Financial Statements

Benjamin Graham

The original — and still the clearest — explanation of why working-capital trends matter more than headline earnings.

View on Amazon →
Quality of Earnings

Quality of Earnings

Thornton L. O'glove

Out of print, expensive, worth it. The chapter on receivables-vs-revenue divergence applies almost word-for-word to most distressed filings.

View on Amazon →